Galapagos reports that the last patient in DARWIN 1 has

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatment
  • Last of 599 enrolled rheumatoid arthritis patients has completed the 12 week visit with filgotinib (GLPG0634) or placebo
  • Triggers start of final 12 week data collection, followed by completion of data verification and data analysis
  • Topline 12 week results expected to be released by mid-April 2015

MECHELEN, Belgium, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG), a clinical stage biotechnology company focused on developing novel mode of action medicines, announces that the last patient in the DARWIN 1 trial with filgotinib has completed the 12 week visit.  This last patient's 12 week visit triggers the clinical research organization's process of final 12 week data collection from all 599 patients enrolled in the trial, to be followed by database lock and analysis.  As this process takes approximately 7 to 8 weeks, Galapagos expects to announce topline results by mid-April 2015.

Selective JAK1 inhibitor filgotinib has demonstrated a potential best-in-class profile in two 4-week Phase 2A trials in RA patients.  Filgotinib is currently in a global Phase 2B program (DARWIN 1, 2 and 3) in 886 RA patients and in a Phase 2 trial in 180 patients with Crohn's disease. 

DARWIN 1 is a 24 week double-blind, placebo-controlled trial that enrolled 599 patients with moderate to severe rheumatoid arthritis who inadequately responded to methotrexate; all patients remain on their background therapy of methotrexate.  This trial evaluates three doses of filgotinib, as once- and twice-daily administration.  In mid-April Galapagos expects to report topline results on the first 12 weeks of treatment, whereas the trial continues for an additional 12 weeks of treatment.  Topline data from 24 weeks' treatment in DARWIN 1 is expected in July 2015.

Topline results from 12 weeks' treatment in DARWIN 1 will include unblinded ACR20 (primary endpoint) scores and other significant secondary endpoints, as well as important lab and safety information.  Frequency of rare events, including severe adverse events, will be disclosed but will remain blinded until disclosure of the 24 week treatment topline data, to ensure the double-blind character of the DARWIN program.  

"We look forward to the 12 week topline results of DARWIN 1 in mid-April," said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos. "We see 98% of eligible patients who complete DARWIN 1 and 2 enrolling in DARWIN 3, with 400 patients now in the long term extension study.  The fact that investigators and patients see benefit in continuing treatment with filgotinib gives confidence."

About data management

Data management is a labor-intensive key step in clinical trials such as DARWIN.  It is highly regulated since the data collected will be used for statistical analysis and report writing and will subsequently be subject to regulatory review.  The data must reflect the medical records of the patients in the study, the source data as collected and stored at the study site. Therefore, the data collected on case report forms will be verified with the records in the hospitals, worldwide.  All the data collected will be checked for missing, outlying or inconsistent values.  When the data are complete and fully verified, the database is locked, such that data can no longer be changed.  Only after this, the data analysis and statistical evaluation can start.  This will finally lead to a set of analyzed data and a statistical analysis report.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications.  In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of filgotinib .  Filgotinib is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2b studies in RA and in Phase 2 in Crohn's disease.  GLPG1205 , a first-in-class inhibitor of GPR84, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients.  GLPG1690 is a compound that targets pulmonary diseases and is currently in a Phase 1 trial.  AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene.  Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage.  The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.  Further information at: www.glpg.com

CONTACT

Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir@glpg.com

Galapagos forward-looking statements

This release may contain forward-looking statements, including, without limitation, statements concerning the safety and efficacy of filgotinib and the expected timing of the release of topline 12-week results from the DARWIN trials and the expected timing and announcement of topline 24-week results from the DARWIN  trials, expectations regarding the commercial potential of our product candidates generally, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," "continues," "we believe," "we intend," as well as similar expressions.  Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements and estimating the commercial potential of our product candidates. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

HUG#1896325

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 49

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 360

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 0

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 349

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 98

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 16

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 138

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 548

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading

Top 5 Most Recently Viewed Articles

TuHURA Biosciences to Showcase Innovations at Major Investment Event

Updated Category News Views 109

TuHURA Biosciences to Present at Investment Conference TuHURA Biosciences, Inc. (NASDAQ: HURA), a pioneering Phase 3 immune-oncology company at the forefront of developing innovative therapeutics, has announced a significant presentation in the investment world. Management is set to showcase their work at the 27th Annual H.C. Wainwright Global Investment Conference, an...

Continue Reading
PennantPark Investment Corporation Enhances CLO Management Strategy

Updated Category News Views 123

PennantPark Investment Corporation Expands CLO Platform MIAMI — PennantPark Investment Corporation (the “Company”) (NYSE: PNNT) has successfully established a strong foothold in the middle market with the recent closing of a $400.5 million debt securitization through its joint venture, PennantPark Senior Loan Fund, LLC ("PSLF"). This significant achievement is part...

Continue Reading
Freeport-McMoRan Exceeds Earnings Expectations Amid Rising Copper Prices

Updated Category News Views 50

Freeport-McMoRan Exceeds Earnings Estimates In a recent financial report, Freeport-McMoRan (NYSE: FCX) showcased its ability to navigate the dynamic mining landscape, particularly benefitting from the surge in copper prices. The company announced a substantial profit that surpassed third-quarter expectations, drawing significant attention from investors and analysts...

Continue Reading
WellsCare and Celltrion Canada Unite for Pain Relief Solutions

Updated Category News Views 126

WellsCare Expands Reach with Celltrion Partnership WellsCare, a pioneering medical technology startup based in South Korea, has forged a promising alliance with Celltrion Canada, a renowned subsidiary of global biopharmaceutical giant Celltrion. This collaboration marks a significant milestone in the development of advanced wearable technology aimed at offering effective...

Continue Reading
Elon Musk Addresses Violence Concerns Amid Political Tensions

Updated Category News Views 524

Elon Musk Issues Stark Warning on Violence at Rally Elon Musk stirred significant debate after his virtual appearance at a far-right rally in the UK, where he alerted attendees to an impending threat of violence. His stark statement, "violence is coming, fight back, or die," has reverberated through political discussions and media outlets alike. Details of the Rally...

Continue Reading